Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name: | Afatinib | Assay: | 99% |
Standard | Enterprise standard | Appearance: | White Crystalline Powder |
CAS NO | 439081-18-2 | EINECS | 1308068-626-2 |
Minimum order quantity | 500g | Packing: | 1kg/aluminum foil bag; 25kg/drum |
Item | Requirements | Test Results |
Description | Off-white powder | Off-white powder |
Identification | HPLC ,NMR | Complies |
Residue on Ignition | ≤0.10% | 0.05% |
Loss on Drying | ≤0.50% | 0.15% |
Heavy Metal | ≤20ppm | <20ppm |
Purity(HPLC) | ≥99.0% | 99.99% |
Conclusion | It complies with EnterpriseStandard |
Function:
Afatinib is a drug approved for the treatment non-small cell lung carcinoma(NSCLC), developed by Boehringer Ingelheim.It acts as a angiokinase inhibitor.Like lapatinib and neratinib, afatinib is a tyrosine kinase inhibitor (TKI) that also irreversibly inhibits human epidermal growth fector receptor 2 (Her2) and epidermal growth fector receptor (EGFR) kinases. Afatinib is not only active against EGFR mutations targeted by first generation TKIs likeerlotinib or gefitinib, but also against those not sensitive to these standard therapies. Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers.Application:
1. Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that also irreversibly inhibits human epidermal growth fector receptor 2 (Her2) and epidermal growth fector receptor (EGFR) kinases.
2. Afatinib is not only active against EGFR mutations targeted by first generation TKIs like erlotinib or gefitinib, but also against mutations such as T790M which are not sensitive to these standard therapies.Because of its additional activity against Her2, it is being investigated for breast cancer as well as other EGFR and Her2 driven cancers.
3. Afatinib is a drug for the first-line treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC).It acts as an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth fector receptor (EGFR) and erbB-2 (HER2).
As a professional health product supplier, we can customize Afatinib powder with different packing, Afatinib capusel with different bottles according to your formula and requests.
>Click here to get more information
Fladrafinil | ≥98.0% HPLC | 90212-80-9 |
Picamilon (Sodium) | ≥98%~101%Titration | 62936-56-5 |
Sunifiram | ≥99.5% HPLC | 314728-85-3 |
Unifiram | ≥99.0% HPLC | 272786-64-8 |
Tianeptine acid | ≥99.0% HPLC | 66981-73-5 |
Tianeptine sodium | ≥99.0% HPLC | 30123-17-2 |
Tianeptine Hemisukfate Monohydrate | ≥98.0%~102.0% HPLC | 66981-73-5 |
Galantamine Hydrobromide | ≥99.0% HPLC | 69353-21-5 |
Galanthamine | ≥99.0% HPLC | 357-70-0 |
Huperzine A | ≥1.0% and 99% HPLC | 102518-79-6 |
NSI-189 Freebase | ≥99.0% HPLC | 1270138-40-3 |
NSI-189 Phosphate | ≥99.0% HPLC | 1270138-41-4 |
PRL-8-53 | ≥99.0% HPLC | 51352-87-5 |
agomelatine | ≥99.0% HPLC | 138112-76-2 |
5a hydroxy laxogenin | ≥99.0% HPLC | 56786-63-1 |
Vincamine | ≥99.0% HPLC | 1617-90-9 |
Centrophenoxine | ≥99.0% HPLC | 3685-84-5 |
N-coumaroyldopamine | ≥99.0% HPLC | 103188-46-1 |
N-caffeoyldopamine | ≥99.0% HPLC | 103188-49-4 |
Goods weight |
Packing |
Shipping method |
Lead-time |
1-50kg |
Below 5kg Use Foil bag;5-25kg use two layer PP bag,then into master carton or cardboard drum |
International express |
1~3 days after your payment |
100-200kg |
25kg/drum,use two layer PP bag,then into cardboard drum |
Air shipping Sea Shipping |
3~5 days after your payment |
Over 500kg |
25kg/drum,use two layer PP bag,then into cardboard drum |
Sea shipping |
5~10 days after your payment |
Q1: Can I get some free sample?